Pitfalls in conducting prospective trials in stage III cardiac amyloidosis - experience from the REVEAL study.

about

Pitfalls in conducting prospective trials in stage III cardiac amyloidosis - experience from the REVEAL study.

Item

http://www.wikidata.org/entity/Q49563182

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Pitfalls in conducting prospec ...... erience from the REVEAL study.

@en

Pitfalls in conducting prospec ...... erience from the REVEAL study.

@nl

type

Item

label

Pitfalls in conducting prospec ...... erience from the REVEAL study.

@en

Pitfalls in conducting prospec ...... erience from the REVEAL study.

@nl

prefLabel

Pitfalls in conducting prospec ...... erience from the REVEAL study.

@en

Pitfalls in conducting prospec ...... erience from the REVEAL study.

@nl

P1476

Pitfalls in conducting prospec ...... erience from the REVEAL study.

@en

P2093

Ashutosh D Wechalekar

http://www.w3.org/2001/XMLSchema#string

Carol J Whelan

http://www.w3.org/2001/XMLSchema#string

Julian D Gillmore

http://www.w3.org/2001/XMLSchema#string

Laura Clifton-Hadley

http://www.w3.org/2001/XMLSchema#string

Marianna Fontana

http://www.w3.org/2001/XMLSchema#string

Paul Smith

http://www.w3.org/2001/XMLSchema#string

Philip N Hawkins

http://www.w3.org/2001/XMLSchema#string

Shameem Mahmood

http://www.w3.org/2001/XMLSchema#string

Stephen Nash

http://www.w3.org/2001/XMLSchema#string

Toyin Adedayo

http://www.w3.org/2001/XMLSchema#string

P2860

Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component.

Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study.

Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis.

Light chain amyloidosis: the heart of the problem.

AL amyloidosis treated with induction chemotherapy with VAD followed by high dose melphalan and autologous stem cell transplantation.

A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis.

Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma.

Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case–control study on 174 patients

P304

242-244

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/13506129.2017.1385453

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Helen J Lachmann

Elizabeth H Phillips

P577

2017-10-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28984490

http://www.w3.org/2001/XMLSchema#string